Navigation Links
Calcium and vitamin D improve bone density in patients taking antiepileptic drugs
Date:11/7/2013

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs (AEDs). The results published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggest that risedronate, a bisphosphonate, may help to prevent new vertebral fractures when taken with calcium and vitamin D supplementation.

Many patients with epilepsy are required to take chronically an AED such as phenytoin, phenobarbital, carbamazepine, primidone, and valproate alone or in combination to control seizures. There is much medical evidence reporting that these AEDs may accelerate bone loss, increasing the risk of osteoporotic fractures. In fact, previous studies found that more than 50% of adults with epilepsy who use AEDs showed decreased bone mass in their hips or spine and the overall fracture risk of patients with epilepsy is considered to be larger than the normal population.

"Long-term use of AEDs is associated with loss of bone mass and increased risk of osteoporosis," explains Dr. Antonio Lazzari with the VA Boston Healthcare System in Massachusetts and lead author of the present study. "Our study is the first longitudinal trial of a bisphosphonate (risedronate), along with calcium and vitamin D supplementation, in preventing and treating bone loss in male veterans with epilepsy receiving AED therapy."

The antiepileptic drug and osteoporosis prevention trial (ADOPT) was a prospective two-year randomized, double-blind, placebo-controlled phase IV clinical trial of 80 male veterans with epilepsy who were treated with an AED for a minimum of two years. All participants received calcium and vitamin D supplements, and were randomized to risedronate or placebo. Subjects received total body, hip, and spine bone density assessments at baseline, one year and two years following their study enrollment.

Baseline characteristics of subjects were similar and 53 patients completed the two-year study. Significant improvement in bone density compared to baseline was observed in 69% and 70% of patients in the placebo and active drug groups, respectively. Patients taking risedronate displayed a significant increase in bone density at the lumbar spine, compared to subjects in the placebo group.

Dr. Lazzari concludes, "Our findings suggest calcium and vitamin D with or without risedronate improves bone density in epilepsy patients taking AEDs. However five new vertebral fractures were observed in the placebo group and none in the active medication group. Adding risedronate to the supplements appears to prevent new fractures in this group of veterans."

The authors caution that therapy with antiresorptive agents should be limited to five years to reduce side effects associated with long-term use of this group of drugs including osteonecrosis of the jaw and atypical femoral fractures. Researchers recommend future studies of efficacy and safety with the long-term use of bisphosphonates in patients with epilepsy.


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related biology news :

1. Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women
2. Calcium linked to increased risk of heart disease and death in patients with kidney disease
3. Calcium and vitamin D help hormones help bones
4. Magnesium may be as important to kids bone health as calcium
5. Calculating phosphorus and calcium concentrations in meat and bone meal for pig diets
6. Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy
7. Waste removal in worms reveals new mechanism to regulate calcium signaling
8. Hebrew University study finds key mechanism in calcium regulation
9. Community-based nutrition education shown to be successful in increasing calcium intake
10. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
11. Calcium supplements remain a valuable tool for maintaining bone health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... media products engineered to radically streamline culture processes, minimize processing time, significantly ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") ... presented at the Company,s Annual and Special Meeting. ... take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, Calgary, ... of meeting and management information circular, containing the matters to ...
Breaking Biology Technology: